£9.0M
AIPO Fund led the strategic investment to fund product development and US market entry.
"We’re entering a transformative period for Adtec Healthcare. This investment from AIPO Fund and SG Biomedical not only provides the capital we need to expand globally but also reflects shared confidence in our vision: to make Cold Plasma a globally recognised and adopted standard in infection control and wound care. We’re proud of what our team has built, and excited to move forward with strong, experienced partners by our side."